Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[New exigencies for new antidepressive agents]

D Ginestet1, J P Olié

  • 1Hôpital Paul Brousse, Villejuif.

L'Encephale
|April 1, 1994
PubMed
Summary

Preclinical and clinical trials for new antidepressant compounds involve extensive safety and efficacy evaluations. Methodological advancements aim to standardize drug assessment but may question future inventive clinical practices.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Addictive behaviors: Clinical facts].

Bulletin de l'Academie nationale de medecine·2020
Same author

Balneotherapy Together with a Psychoeducation Program for Benzodiazepine Withdrawal: A Feasibility Study.

Evidence-based complementary and alternative medicine : eCAM·2016
Same author

[Controlled drug consumption rooms].

Bulletin de l'Academie nationale de medecine·2014
Same author

Deficit of cognitive inhibition in depressed elderly: a neurocognitive marker of suicidal risk.

Journal of affective disorders·2012
Same author

Correlations of cerebello-thalamo-prefrontal structure and neurological soft signs in patients with first-episode psychosis.

Acta psychiatrica Scandinavica·2011
Same author

Association of Disrupted in Schizophrenia 1 (DISC1) missense variants with ultra-resistant schizophrenia.

The pharmacogenomics journal·2010

Area of Science:

  • Pharmacology and clinical trial methodology.
  • Drug development and regulatory science.

Context:

  • Preclinical studies focus on animal toxicology and behavior.
  • Clinical trials in humans require efficacy, safety, drug interaction, and population-specific data.
  • Heterogeneity in antidepressant trial data arises from patient populations and prescriber types.

Purpose:

  • To outline key questions and considerations for human clinical trials of new antidepressant compounds.
  • To discuss factors contributing to information heterogeneity in antidepressant drug development.
  • To evaluate the impact of current methodological advancements on clinical practice and discovery.

Summary:

  • Clinical trials must confirm superiority over placebo, assess long-term efficacy and safety, define populations, and investigate drug interactions, especially in aging subjects.
  • Regulatory bodies like the Marketing Authorization Committee assess the risk-benefit ratio, indications, and medical benefit of new antidepressants.
  • The abstract questions whether current methodological procedures will foster new discoveries or stifle inventive clinical practice.

Impact:

  • Highlights the complex requirements for bringing new antidepressants to market.
  • Underscores the challenges in standardizing clinical trial data for novel psychotropic medications.
  • Raises critical questions about the future of innovation in antidepressant research and clinical application.

Related Experiment Videos